Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in Interest ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

SAB Biotherapeutics (SABS) Free Cash Flow (2020 - 2025)

SAB Biotherapeutics (SABS) has disclosed Free Cash Flow for 6 consecutive years, with -$16.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow fell 74.98% year-over-year to -$16.8 million, compared with a TTM value of -$44.8 million through Dec 2025, down 29.3%, and an annual FY2025 reading of -$45.7 million, down 31.99% over the prior year.
  • Free Cash Flow was -$16.8 million for Q4 2025 at SAB Biotherapeutics, down from -$13.1 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $7.6 million in Q1 2021 and bottomed at -$16.8 million in Q4 2025.
  • Average Free Cash Flow over 5 years is -$7.0 million, with a median of -$7.5 million recorded in 2021.
  • The sharpest move saw Free Cash Flow tumbled 72069.97% in 2021, then skyrocketed 85.07% in 2023.
  • Year by year, Free Cash Flow stood at -$7.2 million in 2021, then surged by 76.9% to -$1.7 million in 2022, then plummeted by 707.91% to -$13.5 million in 2023, then increased by 29.06% to -$9.6 million in 2024, then plummeted by 74.98% to -$16.8 million in 2025.
  • Business Quant data shows Free Cash Flow for SABS at -$16.8 million in Q4 2025, -$13.1 million in Q3 2025, and -$7.2 million in Q2 2025.